Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for rare leg lymphoma: lenalidomide shows promise in relapsed patients

NCT ID NCT01556035

Completed Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen May 14, 2026 · Last updated Jun 12, 2026 · Updated 4 times

Summary

This study tested the drug lenalidomide in 19 people with a rare type of skin lymphoma (leg-type) that returned or did not respond to initial chemotherapy plus rituximab. The goal was to see if lenalidomide could shrink tumors and control the disease. Results will help decide if this drug should be used as a maintenance therapy to prevent future relapses.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY PRIMARY-CUTANEOUS LARGE B-CELL LYMPHOMA (LEG-TYPE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • AP-HM Hôpital Nord

    Marseille, 13915, France

  • AP-HP Groupe hospitalier Bichat - Claude Bernard

    Paris, 75877, France

  • AP-HP Groupe hospitalier Cochin

    Paris, 75679, France

  • AP-HP Hôpital Ambroise Paré

    Boulogne-Billancourt, 92104, France

  • AP-HP Hôpital Avicenne

    Bobigny, 93009, France

  • AP-HP Hôpital Henri Mondor

    Créteil, 94010, France

  • AP-HP Hôpital Tenon

    Paris, 75970, France

  • AP-HP- Hôpital Saint Louis

    Paris, 75475, France

  • CHRU de Montpellier Hôpital Saint-Eloi

    Montpellier, 34295, France

  • CHU Amiens, Hôpital Sud

    Amiens, 80054, France

  • CHU Besançon, Hôpital Saint-Jacques

    Besançon, 25030, France

  • CHU Lyon Sud

    Pierre-Bénite, 69450, France

  • CHU de Bordeaux Hôpital du Haut Lévèque

    Pessac, 33604, France

  • CHU de Clermont-Ferrand, Estaing

    Clermont-Ferrand, 63003, France

  • CHU de Dijon, Le Bocage

    Dijon, 21079, France

  • CHU de Grenoble

    Grenoble, 38043, France

  • CHU de Lille Hôpital Claude Huriez

    Lille, 59037, France

  • CHU de Nantes, Hôtel Dieu

    Nantes, 44093, France

  • CHU de Nice Groupe hospitalier l'Archet

    Nice, 06202, France

  • CHU de Reims, Hôpital Robert Debré

    Reims, 51092, France

  • CHU de Rouen, Hôpital Charles Nicolle

    Rouen, 76031, France

  • CHU de Toulouse Hôpital Larrey

    Toulouse, 31059, France

  • CHU de Tours- Hôpital Trousseau

    Tours, 37044, France

  • Centre Léon Bérard

    Lyon, 69373, France

Conditions

Explore the condition pages connected to this study.

REFRACTORY PRIMARY-CUTANEOUS LARGE B-CELL LYMPHOMA (LEG-TYPE)